Epidemiology of hepatocellular carcinoma in Japan
Epidemiology of hepatocellular carcinoma in Japan
复制标题
DOI：
10.1111/j.1872-034x.2007.00169.x
复制
发表时间：
2007-09-01
影响因子：
4.2
通讯作者：
Kiyosawa, Kendo
中科院分区：
文献类型：
--
作者：
Umemura, Takeji;Kiyosawa, Kendo
在日本，95%是肝细胞癌(肝细胞癌)的原发性肝癌在男性中排名第三，在女性中排名第五。尽管日本的肝癌死亡人数和死亡率在2002年之前一直在上升，但2003年每年的死亡人数(34089人)和死于肝癌的死亡率(27.0/10万)有所下降。丙型肝炎病毒(丙型肝炎病毒)相关的肝癌占日本所有肝癌的75%。在日本，无乙肝表面抗原(HBs)或抗-HCV的肝细胞癌的发病率占全部肝细胞癌的7-12%，一半的非B非C-肝细胞癌的发病原因不明。在地理上，日本西部的肝癌比东部更常见，每个县的肝癌死亡率与抗-丙型肝炎病毒的流行率相关，但与乙肝表面抗原的流行率无关。慢性丙型肝炎的干扰素治疗降低了发生肝癌的危险因素，特别是在持续应答的患者中。
Primary liver cancer, 95% of which is hepatocellular carcinoma (HCC), has ranked third in men and fifth in women as a cause of death from malignant neoplasm in Japan. Although the number of deaths and death rates from HCC increased until 2002 in Japan, annual deaths (34 089) and the death rate (27.0/100 000) from liver cancer decreased in 2003. Hepatitis C virus (HCV)-related HCC represents 75% of all HCC in Japan. The incidence of HCC without hepatitis B surface antigen (HBsAg) or anti-HCV accounted for 7-12% of HCC in Japan and half of non-B non-C-HCC was of unknown origin. Geographically, HCC is more frequent in western than eastern Japan, and the death rates from HCC in each prefecture correlate with the prevalence of anti-HCV, but not with HBsAg prevalence. Interferon therapy for chronic hepatitis C has reduced the risk factors for development of HCC, especially among patients with sustained response.